Oct 29 2009
-
Strong third quarter: drug sales up 9.4% at constant currency
-
Dynamic Specialty care franchise: 16.7% sales growth at constant currency
-
First nine months drug sales up 7.1% year-on-year at constant currency
-
Group financial objectives updated
Ipsen (Paris:IPN) reported its sales for the third quarter and first nine months of 2009.
Third quarter and first nine months of 2009 unaudited IFRS consolidated sales
Commenting on the first nine month performance, Jean-Luc Bélingard, Chairman and Chief Executive Officer of Ipsen said: “Ipsen’s first nine months performance continued to show good growth across all specialist care products in all regions. One year after the closing of our US acquisitions, all the building blocks are now in place to ensure long-term growth, through the successful launches of Somatuline® Depot, Increlex®, Dysport® and Apokyn®. The broadening of Somatuline®’s indications, with NET - US Phase III clinical trial currently starting - and the combination of recombinant human growth hormone (rhGH) and recombinant human insulin-like growth factor-1 (rhIGF-1), - currently in Phase II, represent two major opportunities for the long term growth of the Group.” Jean-Luc Bélingard added: “We take pride in the timely delivery of all the identified milestones so far this year. In oncology, BN-83495 has moved into phase II, Decapeptyl® 6 month was given a collective green light in Europe, and we have successfully optimised our pipeline, notably with the licensing out of CDC25 to Debiopham and the redesign of the Group’s collaboration with Spirogen for SJG-136, a DNA minor groove binding agent. In endocrinology and beyond our US focus, BIM-23A760, our first-in-class chimeric compound has moved into phase II and shows encouraging signs of efficacy in acromegaly. In neurology, Dysport® was approved by the FDA and is currently being launched. In haematology, we are now ready to initiate phase III for OBI-1, our recombinant porcine FVIII . On the primary care front, we have also delivered on a rich deal for Ipsen on Adenuric®, bringing to patients the first innovation in the treatment of gout in many decades.” Jean-Luc Bélingard concluded: “More globally, with its rich and balanced pipeline, we believe the Group is poised to benefit from multi company-transforming opportunities and set to continue to outpace industry growth.”